In this issue:
Cetuximab + FOLFOX-4 active in mCRC
Cetuximab + capecitabine: increased toxicity
Bevacizumab + irinotecan + 5-FU/LV in mCRC
Bevacizumab + common CT regimens in mCRC
XELOX vs FOLFOX4: first-line in mCRC
Prolonging bevacizumab improves outcomes
Peri-operative chemotherapy advantageous
Incorporating panitumumab in mCRC regimens
Benefits with cetuximab dose-escalation
FDG-PET may reduce futile laparotomies
Download PDF